The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Esposito Pamela since 2018.
This trader's CIK number is 1744425.
At the time of last reporting, Esposito Pamela was the Officer of Kymera Therapeutics, Inc.. (stock ticker symbol KYMR).
Also see all insider trading activities at Kymera Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | KYMR | 0 | $0 | 5,000 | $245,185 | 5,000 | $147,750 |
| 2024 | KYMR | 0 | $0 | 16,000 | $773,861 | 16,000 | $369,052 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | REPL | 0 | $0 | 51,624 | $1,048,585 | 45,658 | $386,131 |
| 2022 | REPL | 0 | $0 | 18,507 | $426,617 | 15,000 | $15,150 |
| 2021 | REPL | 0 | $0 | 107,000 | $4,203,687 | 107,000 | $542,768 |
| 2020 | REPL | 0 | $0 | 21,000 | $656,770 | 84,294 | $151,489 |
| 2019 | REPL | 0 | $0 | 0 | $0 | 25,700 | $44,975 |
| 2018 | REPL | 0 | $0 | 0 | $0 | 87,000 | $152,250 |
1. Kymera Therapeutics, Inc. (KYMR)
2. Replimune Group, Inc. (REPL)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-03 | KYMR | Option Ex | 5,000 | 29.55 | 147,750 |
| 2025-06-03 | KYMR | Sale | 5,000 | 49.04 | 245,185 |
| 2024-12-02 | KYMR | Option Ex | 2,500 | 29.55 | 73,875 |
| 2024-12-02 | KYMR | Sale | 2,500 | 49.00 | 122,500 |
| 2024-09-17 | KYMR | Sale | 13,500 | 48.25 | 651,361 |
| 2024-09-17 | KYMR | Option Ex | 13,500 | 21.86 | 295,177 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-11 | REPL | Option Ex | 5,358 | 3.30 | 17,681 |
| 2023-09-12 | REPL | Option Ex | 300 | 3.30 | 990 |
| 2023-09-11 | REPL | Sale | 5,358 | 20.01 | 107,213 |
| 2023-09-12 | REPL | Sale | 300 | 20.00 | 6,000 |
| 2023-08-22 | REPL | Option Ex | 18,600 | 9.40 | 174,840 |
| 2023-08-22 | REPL | Sale | 18,600 | 20.01 | 372,186 |
| 2023-08-11 | REPL | Option Ex | 1,400 | 3.30 | 4,620 |
| 2023-08-11 | REPL | Sale | 1,400 | 20.00 | 28,000 |
| 2023-07-10 | REPL | Option Ex | 20,000 | 9.40 | 188,000 |
| 2023-07-10 | REPL | Sale | 20,000 | 21.38 | 427,500 |
| 2023-05-16 | REPL | Sale | 5,966 | 18.05 | 107,686 |
| 2022-12-09 | REPL | Option Ex | 15,000 | 1.01 | 15,150 |
| 2022-12-09 | REPL | Sale | 15,000 | 25.03 | 375,450 |
| 2022-05-16 | REPL | Sale | 3,507 | 14.59 | 51,167 |
| 2021-08-04 | REPL | Option Ex | 4,200 | 15.50 | 65,100 |
| 2021-08-05 | REPL | Option Ex | 25,800 | 15.50 | 399,900 |
| 2021-08-04 | REPL | Sale | 4,200 | 35.00 | 147,000 |
| 2021-08-05 | REPL | Sale | 25,800 | 35.09 | 905,322 |
| 2021-07-20 | REPL | Sale | 4,862 | 33.05 | 160,689 |
| 2021-07-21 | REPL | Sale | 12,538 | 33.17 | 415,885 |
| 2021-07-21 | REPL | Option Ex | 12,538 | 1.01 | 12,663 |
| 2021-07-20 | REPL | Option Ex | 4,862 | 1.01 | 4,910 |
| 2021-07-15 | REPL | Option Ex | 4,600 | 1.01 | 4,646 |
| 2021-07-15 | REPL | Sale | 4,600 | 33.37 | 153,502 |
| 2021-01-19 | REPL | Option Ex | 5,727 | 1.01 | 5,784 |
| 2021-01-15 | REPL | Sale | 29,273 | 43.58 | 1,275,717 |
| 2021-01-14 | REPL | Sale | 20,000 | 45.02 | 900,400 |
| 2021-01-15 | REPL | Option Ex | 29,273 | 1.01 | 29,565 |
| 2021-01-14 | REPL | Option Ex | 20,000 | 1.01 | 20,200 |
| 2021-01-19 | REPL | Sale | 5,727 | 42.81 | 245,172 |
| 2020-12-23 | REPL | Option Ex | 50,704 | 1.75 | 88,732 |
| 2020-12-11 | REPL | Option Ex | 12,590 | 3.30 | 41,547 |
| 2020-10-14 | REPL | Sale | 16,000 | 32.59 | 521,520 |
| 2020-10-14 | REPL | Option Ex | 16,000 | 1.01 | 16,160 |
| 2020-08-31 | REPL | Option Ex | 5,000 | 1.01 | 5,050 |
| 2020-08-31 | REPL | Sale | 5,000 | 27.05 | 135,250 |
| 2019-12-20 | REPL | Option Ex | 25,700 | 1.75 | 44,975 |
| 2018-12-13 | REPL | Option Ex | 87,000 | 1.75 | 152,250 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Esposito Pamela (Officer of Kymera Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.